The last decade has witnessed a paradigm shift in cancer therapy, from non-specific cytotoxic chemotherapies to agents targeting specific molecular mechanisms. Nonetheless, cardiovascular toxicity of cancer therapies remains an important concern. This is particularly relevant given the significant improvement in survival of solid and haematological cancers achieved in the last decades. Cardio-oncology is a subspecialty of medicine focusing on the identification and prevention of cancer therapy–related cardiovascular toxicity (CTR-CVT). This review will examine the new definition of CTR-CVT and guiding principles for baseline cardiovascular assessment and risk stratification before cancer therapy, providing take-home messages for non-specialized cardiologists.

中文翻译：

---

新型抗癌药物的使用：心脏病专家需要了解什么

过去十年见证了癌症治疗的范式转变，从非特异性细胞毒性化疗到针对特定分子机制的药物。尽管如此，癌症治疗的心血管毒性仍然是一个重要问题。鉴于过去几十年实体癌和血液癌生存率的显着改善，这一点尤其重要。心脏肿瘤学是医学的一个亚专业，专注于识别和预防癌症治疗相关的心血管毒性（CTR-CVT）。这篇综述将探讨 CTR-CVT 的新定义以及癌症治疗前基线心血管评估和风险分层的指导原则，为非专业心脏病专家提供重要信息。